Weekly paclitaxel: An effective and well-tolerated treatment in patients with advanced breast cancer

Critical Reviews in Oncology/Hematology

Volumn 44, Issue SUPPL., 2002, Pages 15-30

  Lück, Hans Joachim ^a   Roché, Henri ^b  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b Centre Caudius Régaud   (France)

Author keywords

Advanced breast cancer; Chemoradiotherapy; Combination chemotherapy; HER2; Trastuzumab; Weekly paclitaxel

Indexed keywords

ANTHRACYCLINE DERIVATIVE; CISPLATIN; CYTOTOXIC AGENT; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; FOLINIC ACID; IMMUNOMODULATING AGENT; MONOCLONAL ANTIBODY; NAVELBINE; PACLITAXEL; PLATINUM; TRASTUZUMAB; UFT;

ADVANCED CANCER; BREAST CARCINOMA; CANCER RADIOTHERAPY; CELL DIVISION; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DOSE CALCULATION; DRUG DELIVERY SYSTEM; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG RESEARCH; DRUG RESPONSE; DRUG TOLERANCE; EXPOSURE; HUMAN; NEUROPATHY; NEUTROPENIA; PERIPHERAL NEUROPATHY; PREMEDICATION; REVIEW; TOXICITY; TUMOR CELL;

EID: 0037185036     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1040-8428(02)00105-1     Document Type: Review

References (92)

1. Greenlee R.T., Hill-Harmon M.B., Murray T., et al. Cancer statistics, 2001. CA Cancer J. Clin. 51:2001;15-36.
2. Ellis M.J., Hayes D.F., Lippman M.E. Treatment of metastatic breast cancer. Harris J.R., Lippmann M.E., Morrow M., et al. Diseases of the breast. 2000;749-798 Lippincott Williams & Wilkins, Philadelphia, PA.
3. Perez E.A. Paclitaxel in breast cancer. Oncologist. 3:1998;375-389.
4. Mamounas E., Brown A., Fisher B., et al. 3-hour (hr) high dose Taxol (T) infusion in advanced breast cancer (ABC): an NSABP phase II study. Proc. Am. Soc. Clin. Oncol. 14:1995;127.
5. Seidman A.D., Tiersten A., Hudis C., et al. Phase II trial of paclitaxel by 3-hour infusion as initial and salvage chemotherapy for metastatic breast cancer. J. Clin. Oncol. 13:1995;2575-2581.
6. Davidson N.G. Single-agent paclitaxel as first-line treatment of metastatic breast cancer: the British experience. Semin. Oncol. 23:(Suppl. 11):1996;6-10.
7. Holmes F.A., Valero V., Walters R.S., et al. The MD Anderson Cancer Center experience with Taxol in metastatic breast cancer. J. Natl. Cancer Inst. Monogr. 15:1993;161-169.
8. Abrams J.S., Vena D.A., Baltz J., et al. Paclitaxel activity in heavily pretreated breast cancer: a national Cancer Institute Treatment Referral Center trial. J. Clin. Oncol. 13:1995;2056-2065.
9. Seidman A.D., Reichman B.S., Crown J.P., et al. Paclitaxel as second and subsequent therapy for metastatic breast cancer: activity independent of prior anthracycline response. J. Clin. Oncol. 13:1995;1152-1159.
10. Perez E.A., Vogel C.L., Irwin D.H., Kirshner J.J., Patel R. Multicenter phase II trial of weekly paclitaxel in women with metastatic breast cancer. J. Clin. Oncol. 19:2001;4216-4223.
11. Seidman A.D., Hudis C.A., Albanel J., et al. Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer. J. Clin. Oncol. 16:1998;3353-3361.
12. Norton L. Evolving concepts in the systemic drug therapy of breast cancer. Semin. Oncol. 24:(Suppl. 10):1997;S10.3-S10.10.
13. Belotti D., Vergani V., Drudis T., et al. The microtubule-affecting drug paclitaxel has antiangiogenic activity. Clin. Cancer Res. 2:1996;1843-1849.
14. Milross C.G., Mason K.A., Hunter N.R., et al. Relationship of mitotic arrest and apoptosis to antitumor effect of paclitaxel. J. Natl. Cancer Inst. 88:1996;1308-1314.
15. Gianni L., Keens C.M., Gianni A., et al. Non-linear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans. J. Clin. Oncol. 13:1995;180-190.
16. Fennelly D., Aghajanian C., Shapiro F., et al. Phase 1 and pharmacologic study of paclitaxel administered weekly in patients with relapsed ovarian cancer. J. Clin. Oncol. 15:1997;187-192.
17. Luftner D., Mergenthaler H.G., Grunewald R., Flath B., Budach V., Possinger K. Paclitaxel in a weekly fractionated schedule advanced breast cancer. Proc. Am. Soc. Clin. Oncol. 15:1996;A266.
18. Seidman A.D., Murphy B., Hudis C., et al. Activity of Taxol by weekly 1-hour infusion in patients (pts) with metastatic breast cancer (MBC): a phase II and pharmacologic study. Proc. Am. Soc. Clin. Oncol. 16:1997;A517.
19. Chang A.Y., Boros L., Asbury R., Hui L., Rubins J. Dose-escalation study of weekly 1-hour paclitaxel administration in patients with refractory cancer. Semin. Oncol. 24:(Suppl. 17):1997;S69-S71.
20. Sikov W., Akerley A., Cummings F., et al. Weekly high-dose paclitaxel in locally advanced (LABC) and metastatic breast cancer (MBC). Proc. Am. Soc. Clin. Oncol. 16:1997;191a. (abstract 669).
21. 2 in pretreated breast (BC) and ovarian cancer (OC). Proc. Am. Soc. Clin. Oncol. 16:1997;A568.
22. Marhenke D, Luck H-J, Scholz U, et al. Weekly paclitaxel for metastatic breast cancer (MBC). 8th Int Congress Anti-Cancer Treatment, 1998 (abstract 016).
23. Asbury R., Chang A., Boros L., Asbury L., Rubins J. Weekly moderate-dose paclitaxel in advanced breast cancer. Semin. Oncol. 26:(Suppl. 18):1999;1997.
24. Breier S, Lebedinsky C, Ayiviri C, et al. Long-term weekly paclitaxel (P) in metastatic breast cancer (MBC). A phase II trial in pretreated patients (pts). Proc Am Soc Clin Oncol 1998;17: (abstract 740).
25. Lluch A, Tormo G, Martinez de Duenas E, Azagra P, Prosper F, Garcia-Conde J. Activity of weekly paclitaxel in breast cancer recurrences after high dose chemotherapy (HDC) with stem cell support. Ninth International Congress on Anti-Cancer Treatment, Paris, 1999 (abstract 0136).
26. Breier S., Lebedinsky C., Ayaviri C., et al. Long-term weekly Taxol® (paclitaxel) injection over 1-hour infusion: a phase II trial report. Breast. Cancer Res. Treat. 57:1999;124. (abstract 523).
27. Mickiewicz E, Alvarez AM, Brosio C, et al. A promising second-line treatment with weekly Taxol (T) in anthracycline recurrent, advanced breast cancer (ABC) patients (pts). Proc Am Soc Clin Oncol 1999;18: (abstract 515).
28. Sola C, Lluch A, Garcia-Conde J, et al. Phase II study of weekly paclitaxel (P) treatment in recurrent breast cancer after high-dose chemotherapy (HDC). Proc Am Soc Clin Oncol 1999;18: (abstract 245).
29. Alvarez AM, Mickiewicz E, Brosio C, et al. Reinduction with weekly Taxol (T) in advanced breast cancer. Proc Am Soc Clin Oncol 1999;18: (abstract 636).
30. Waintraub S.E., Cantwell S., DeVries J. Phase II study to evaluate the efficacy of weekly paclitaxel in patients with metastatic breast cancer who have failed prior anthracycline±taxane±PSCT therapy. Proc. Am. Soc. Clin. Oncol. 19:2000;A470.
31. Sikov W., Akerley W., Strenger R., et al. Weekly high-dose paclitaxel in locally advanced and metastatic breast cancer: a BrUOG study. Semin. Oncol. 26:(Suppl 18):1999;1996.
32. Lück H.J., Scholz U., Kühnle H. Weekly taxanes in treatment of metastatic breast cancer. Cancer Invest. (Suppl.). 18:2000;1-2.
33. Frasci G., Comella P., Parziale A., et al. Cisplatin-paclitaxel weekly schedule in advanced solid tumors: a phase I study. Ann. Oncol. 8:1997;291-293.
34. Frasci G., Comella P., D'Aiuto G., et al. Weekly paclitaxel-cisplatin administration with G-CSF support in advanced breast cancer: a phase II study. Breast Cancer Res. Treat. 49:1998;13-26.
35. Loffler T.M., Freund W., Hausamen T.U. Dose-dense weekly paclitaxel and carboplatin in advanced solid tumors. Proc. Am. Soc. Clin. Oncol. 16:1997;A779.
36. Kohler U., Schiller S., Fuechsel G., Kettner E., Richter B., Ridwelski K. Weekly paclitaxel with epirubicin as second-line therapy of metastatic breast cancer: results of a clinical phase II study. Semin. Oncol. 24:(Suppl. 17):1997;S40-S43.
37. Panday V.R., ten Bokkel Huinink W.W., Rosing H., et al. Phase I and pharmacologic study of weekly doxorubicin and 1 h infusional paclitaxel in patients with advanced breast cancer. Anticancer Drugs. 9:1998;665-673.
38. Jones V., Finucane D., Rodriguez R., et al. Phase II weekly paclitaxel (Taxol) and liposomal doxorubicin (Doxil) in patients with locally advanced and metastatic breast cancer. Proc. Am. Soc. Clin. Oncol. 19:2000;A451.
39. Schwonzen M., Kurbacher C.M., Mallmann P. Liposomal doxorubicin and weekly paclitaxel in the treatment of metastatic breast cancer. Anticancer Drugs. 11:2000;681-685.
40. Uranga G, Ventriglia M, Mohr N, et al. Taxol (T) plus doxorubicin (D) both weekly as primary treatment in advanced breast cancer (ABC). Proc Am Soc Clin Oncol 2000;19: (abstract 472).
41. Nistico C., D'Ottovio A.M., Frontini L., et al. Weekly combination of Taxol, 5-fluorouracil and leucovorin (TFL) in advanced pretreated breast cancer patients. Eur. J. Cancer. 35:(Suppl. 4):1999;327.
42. Loesch D, Dakhil S, Gusfey G, Hopkins J, Rohrbaugh T. Phase II trial of a weekly Taxol (T), 5-fluorouracil (FU) and leucovorin (LV) regimen in patients (pts) with metastatic breast cancer: an update. Proc Am Soc Clin Oncol 1999;18: (abstract 445).
43. D'Ottavio AM, Nisticò S, Valenza R, et al. Weekly combination of Taxol, 5-fluorouracil and leucovorin (TFL) in advanced breast cancer patients (pts). San Antonio Breast Cancer Symposium, 2000 (abstract 333).
44. Lalisang R., Nortier J., Wils J., et al. Dose dense epirubicin (E) and paclitaxel (P) with G-CSF (Filgrastim) in metastatic breast cancer (MBC): a weekly schedule. Proc. Am. Soc. Clin. Oncol. 16:1997;A624.
45. Scholz U., Lück H.-J., Canzler U., Robner D., Kühnle H. UFT/leucovorin combined with paclitaxel for anthracycline-pretreated advanced breast cancer. Oncology. 14:(Suppl. 9):2000;44-46.
46. Gojo I., Tkaczuk K.H. A phase I study of paclitaxel, UFT and leucovorin. Oncology. 14:(Suppl 10):2000;76-78.
47. Lück H-J, Scholz U, Rossner D et al. Phase I study of weekly paclitaxel in combination with oral uracil/Ftorafur (UFT) plus lecovorin (LV) in the treatment of patients (pts) with anthracycline-resistant metastatic breast cancer. Proc Am Soc Clin Oncol 2001;20: (abstract 2024).
48. d Souza P.L., Mueller S., Haden K., Cohen R. Phase I study of weekly vinorelbine in combination with weekly paclitaxel in adult patients with advanced refractory cancer. Proc. Am. Soc. Clin. Oncol. 18:1999;A799.
49. Hainsworth J.D., Burris H.A., Greco F.A. Weekly paclitaxel, doxorubicin and carboplatin in the first-line treatment of patients with metastatic breast cancer. Semin. Oncol. 26:(Suppl. 18):1999;13.
50. Frasci G., D'Aiuto G., Comella P., et al. Cisplatin-epirubicin-paclitaxel weekly administration with G-CSF support in advanced breast cancer: a phase I study of the Southern Italy Cooperative Oncology Group. Breast Cancer Res. Treat. 56:1999;239-252.
51. Frasci G., D'Aiuto G., Comella P., et al. Cisplatin-epirubicin-paclitaxel weekly administration with G-CSF support in advanced breast cancer. A Southern Italy Cooperative Oncology Group (SICOG) phase II study. Breast Cancer Res. Treat. 62:2000;87-97.
52. D'Aiuto G., Frasci G., Carreca I., et al. Weekly cisplatin-epirubicin-paclitaxel with G-CSF support in advanced breast cancer. Proc. Am. Soc. Clin. Oncol. 19:2000;A490.
53. Christofanilli M., Fratarcangeli T., Frye D., et al. Weekly high-dose paclitaxel (HD-P) has significant antitumor activity in inflammatory breast cancer (IBC). Proc. Am. Soc. Clin. Oncol. 20:2001;A1807.
54. Green M.C., Buzdar A.U., Smith T., et al. Weekly paclitaxel (P) followed by FAC in the neo-adjuvant setting provides improved pathologic complete remission (pCR) rates compared to standard paclitaxel followed by FAC therapy. Preliminary results of an ongoing prospective clinical trial. Proc. Am. Soc. Clin. Oncol. 20:2001;129.
55. Gelmon K.A., Tolcher A., O'Reilly S., et al. A phase I-II study of bi-weekly paclitaxel as first-line treatment in metastatic breast cancer. Ann. Oncol. 9:1998;1247-1249.
56. Gelmon K.A., O'Reilly S.E., Tolcher A.W., et al. Phase I/II trial of biweekly paclitaxel and cisplatin in the treatment of metastatic breast cancer. J. Clin. Oncol. 14:1996;1185-1191.
57. Sanchez-Rovira P., Jaen A., Gonzalez-Flores E., et al. Biweekly gemcitabine-adriamycin-paclitaxel combination (GAT) in metastatic breast cancer patients (MBC): results from a phase II trial. Proc. Am. Soc. Clin. Oncol. 19:2000;A423. and poster presented at the annual meeting.
58. Rahal MM, Ezzat AA, Ibrahim EM, et al. Neoadjuvant high-dose sequential chemotherapy with adriamycin (A), paclitaxel (P) and cyclophosphamide (C) is feasible and effective in poor prognostic patients with locally advanced breast cancer (LABC). San Antonio Breast Cancer Symposium, 2000 (abstract 261).
59. Tolcher A., Gelmon K.A. Interim results of a phase I/II study of biweekly paclitaxel and cisplatin in patients with metastatic breast cancer. Semin. Oncol. 22:(Suppl. 8):1995;28-32.
60. Elling D., Krocker J., Kummel S., et al. Dose intensified adjuvant chemotherapy in high risk breast carcinoma with 4-9 positive lymph nodes. Zentralbl. Gynakol. 122:2000;207-216.
61. Lokich J., Anderson N., Moore C., et al. Paclitaxel, cisplatin and etoposide combination chemotherapy: a comparison of dose intensity in two multifractionated dose schemas. Eur. J. Cancer. 34:1998;664-667.
62. Lokich J.J., Anderson N., Bern M., Coco F., Dow E. The multifractionated, twice-weekly dose schedule for a three-drug chemotherapy regimen. Cancer. 85:1999;499-503.
63. Formenti S.C., Symmans W.F., Volm M. Concurrent paclitaxel and radiation therapy for breast cancer. Semin. Radiat. Oncol. 9:(Suppl. 1):1999;34-42.
64. Formenti SC, Spicer D, Skinner K, et al. Pre-operative twice weekly paclitaxel and radiation therapy in locally advanced breast cancer (LABC): molecular determinants of pathological response. Proc Am Soc Clin Oncol 1999;18: (abstract 282).
65. Skinner K.A., Silberman H., Florentine B., et al. Preoperative paclitaxel and radiotherapy for locally advanced breast cancer: surgical aspects. Ann. Surg. Oncol. 7:2000;145-149.
66. Slamon D.J., Clark G.M., Wong S.G., Levin W.J., Ullrich A., McGuire W.L. Human breast cancer: correlation of relapse and survival with amplification of the HER2-2/neu oncogene. Science. 235:1987;177-182.
67. Slamon D.J., Godolphin W., Jones L.A., et al. Studies of the HER-2/neu prot-oncogene in human breast and ovarian cancer. Science. 244:1989;707-712.
68. Seshadri R., Firgaira F.A., Horsfall D.J., McCaul K., Setlur V., Kitchen P. Clinical significance of HER-2/neu oncogene amplification in primary breast cancer. J. Clin. Oncol. 11:1993;1936-1942.
69. Press M.F., Pike M.C., Chazin V.R., et al. HER-2/neu expression in node-negative breast cancer: direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent disease. Cancer Res. 553:1993;4960-4970.
70. Ravdin P.M., Chamness G.C. The c-erbB-2 proto-oncogene as a prognostic and predictive marker in breast cancer: a paradigm for the development of other macromolecular markers - a review. Gene. 159:1995;19-27.
71. Greenberg P.A., Hortobagyi G.N., Smoth T.L., Ziegler L.D., Frye D.K., Buzdar A.U. Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer. J. Clin. Oncol. 14:1996;2197-2205.
72. Pietras J., Fendly B.M., Chazin V.R., Pegram M.D., Howell S.B., Slamon D.J. Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells. Oncogene. 9:1994;1829-1838.
73. Carter P., Presta L., Gorman C.M., et al. Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc. Natl. Acad. Sci. USA. 89:1992;4285-4289.
74. Pietras R.J., Pegram M.D., Finn R.S., Maneval D.A., Slamon D.J. Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs. Oncogene. 17:1998;2235-2249.
75. Pegram M., Hsu S., Lewis G., et al. Inhibitory effects of combinations of HER2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers. Oncogene. 18:1999;2241-2251.
76. Konecny G., Pegram M.D., Beryt M., et al. Therapeutic advantage of chemotherapy drugs in combination with Herceptin against human breast cancer cells with HER2/neu overexpression. Breast Cancer Res. Treat. 57:1999;114.
77. Pietras R.J., Poen J.C., Callardo D., Wongvipat P.N., Lee H.J., Slamon D.J. Monoclonal antibody to HER2/neu receptor modulates repair of radiation-induced DNA damage and enhances radiosensitivity of human breast cancer cells overexpressing this oncogene. Cancer Res. 59:1999;1347-1355.
78. Baselga J., Norton L., Albanell J., Kim Y.M., Mendelsohn J. Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res. 58:1998;2825-2831.
79. Slamon D, Leyland-Jones B, Shak S, et al. Addition of Herceptin™ (humanized anti-HER2 antibody) to first line chemotherapy for HER2 overexpressing metastatic breast cancer (HER2+/MBC) markedly increases anticancer activity: a randomized, multinational controlled phase III trial. Proc Am Soc Clin Oncol 1998;17: (abstract 377).
80. Slamon D., Leyland-Jones B., Shak S., et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 344:2001;783-792.
81. Fornier M, Seidman AD, Esteva FJ, et al. Weekly (W) Herceptin (H)+1 hour Taxol (T): phase II study in HER2 overexpressing (H2+) and non-overexpressing (H2-) metastatic breast cancer (MBC). Proc Am Soc Clin Oncol 1999;18: (abstract 482).
82. Gilewski T., Seidman A., Norton L., Hudis C. An immunotherapeutic approach to treatment of breast cancer: focus on trastuzumab plus paclitaxel. Cancer Chemother. Pharmacol. (Suppl.). 46:2000;S23-S26.
83. Fornier M, Seidman AD, Esteva F, et al. Weekly (W) Herceptin (H) and Taxol (T) for metastatic breast cancer (MBC): correlation of response rate to HER2 immunophenotype [immunohistochemistry (IHC)] and gene amplification [Fluorescent In-Situ Hybridization (FISH)]. Lynn Sage Breast Cancer Symposium, 2000:G1.
84. Seidman AD, Fornier M, Esteva F, et al. Final report: weekly (W) Herceptin (H) and Taxol (T) for metastatic breast cancer (MBC): analysis of efficacy by HER2 immunophenotype [immunohistochemistry (IHC)] and gene amplification [fluorescent in-situ hybridization (FISH)]. Proc Am Soc Clin Oncol 2000;19: (abstract 319) and poster presented at the annual meeting.
85. Bangemann N, Kuhle A, Wilrodt RG, Buehler H, Schaller G. Treatment of HER2 overexpressing metastatic breast cancer (MBC) with trastuzumab (Herceptin®) and chemotherapy. San Antonio Breast Cancer Symposium, 2000 (abstract 530).
86. Scholz U, Luck HJ, Schippert C, Langer-Nitsche C, Kuhnle H. Trastuzumab (Herceptin) combined with weekly paclitaxel in the treatment of metastatic breast cancer: a phase II study. San Antonio Breast Cancer Symposium 2000 (abstract 527).
87. Tsavdaridis D., Timotheadou E., Christodoulou C., et al. Weekly administration of paclitaxel, as first-line chemotherapy, and Herceptin (trastuzumab) in advanced breast cancer (ABC). Ann. Oncol. 11:(Suppl. 4):2000;131P.
88. Burris III HA, Hainsworth JD, Miranda FT, et al. Phase II trial of Herceptin induction followed by combination therapy with paclitaxel and carboplatin: a Minnie Pearl Research Network Trial. San Antonio Breast Cancer Symposium, 2000 (abstract 24).
89. Slamon D.J., Leyland-Jones B., Shak S., et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 344:2001;783-792.
90. Seidman A.D., Fornier M.N., Esteva F.J., et al. Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification. J. Clin. Oncol. 19:2001;2587-2595.
91. Marchetti P, Urien S. Weekly administration of paclitaxel: theoretical and clinical basis. Crit Rev Oncol Hematol 2002;44(suppl.):S3-13.
92. Breier S., Lebedinsky C., Ayaviri C., et al. Long-term weekly paclitaxel over 1 hour infusion with de-escalated premedication. A phase II trial report. Breast Cancer Res. Treat. 57:1999;K4-W160A.